Art. -Nr.: HY-13525

CP-91149

Name: CP-91149
Brand: MedChemExpress
SKU: HY-13525
Price: 60.00 USD
Availability: InStock
Rating: 5 (9 reviews)

9 Cited Publications

Kundenbewertung

Based on 9 publication(s) in Google Scholar

CP-91149 is a GP (glycogen phosphorylase) inhibitor. CP-91149 promotes glycogen resynthesis, but not its overaccumulation. CP-91149 has the potential for Type II (insulin-dependent) diabetes study.

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

Reinheit : 99.84%
CAS. Nr.: 186392-40-5
Formel: C₂₁H₂₂ClN₃O₃
Molecular Weight:399.88

Speicherung:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month

CP-91149 Chemical Structure

CAS. Nr.: 186392-40-5

Größe

Preis

Verfügbarkeit

Menge

Amount: USD 0.00

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biologische Aktivität
- Beschreibung
- Cellular Effect
- In Vitro
Chemical Information
Publications (9)
Lösungsmittel & Löslichkeit
- In Vitro
- In Vivo
Protokoll (2)
Reinheit & Dokumentation
Verweise
Help & FAQs
Classifications
Bioz

Biologische Aktivität

Beschreibung

Cellular Effect

Cell Line	Type	Value	Description	References
Hepatocyte	IC₅₀	3172.5 nM Compound: CP-91149	Inhibition of glycogenolysis in rat hepatocytes assessed as GCN-stimulated glycogen breakdown after 5 mins Inhibition of glycogenolysis in rat hepatocytes assessed as GCN-stimulated glycogen breakdown after 5 mins	[PMID: 32527535]
HepG2	IC₅₀	3310.4 nM Compound: CP-91149	Inhibition of glycogenolysis in human HepG2 cells assessed as GCN-stimulated glycogen breakdown after 5 mins Inhibition of glycogenolysis in human HepG2 cells assessed as GCN-stimulated glycogen breakdown after 5 mins	[PMID: 32527535]
Sf9	IC₅₀	0.082 μM Compound: D; CP-91149	Inhibition of human recombinant liver glycogen phosphorylase A expressed in baculovirus infected Sf9 insect cells assessed as release of phosphate from glucose-1- phosphate in presence of 7.5 mM glucose by malachite green based assay Inhibition of human recombinant liver glycogen phosphorylase A expressed in baculovirus infected Sf9 insect cells assessed as release of phosphate from glucose-1- phosphate in presence of 7.5 mM glucose by malachite green based assay	[PMID: 27624527]
Sf9	IC₅₀	110 nM Compound: CP-91149	Inhibition of recombinant human liver glycogen phosphorylase a expressed in baculovirus-infected Sf9 cells using glucose-1-phosphate as substrate in presence of 7.5 mM glucose Inhibition of recombinant human liver glycogen phosphorylase a expressed in baculovirus-infected Sf9 cells using glucose-1-phosphate as substrate in presence of 7.5 mM glucose	[PMID: 32527535]
SK-HEP1	IC₅₀	1.5 μM Compound: CP-91149	Inhibitory concentration against human SK-Hep-1 cells (hepatoma cell line) Inhibitory concentration against human SK-Hep-1 cells (hepatoma cell line)	[PMID: 15603973]

In Vitro

CP-91149 treatment decreases muscle GP activity by converting the phosphorylated AMP-independent α form into the dephosphorylated AMP-dependent b form and inhibiting GP α activity and AMP-mediated GP b activation^[1].
CP-91149 (10, 30, 50 μM) inhibits brain GP and causes glycogen accumulation in A549 cells^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.

Cell Viability Assay^[1]

View Protocol

Cell Line:

Cells were transduced with adenoviruses and incubated in the presence of 25 mM glucose for 2 days.
Concentration:

10 µM (glucose− or glucose+ for 18 h).
Incubation Time:

3 h.
Result:

Promoted the conversion of GP a into GP b, according to α model proposed in hepatocytes.

Western Blot Analysis^[2]

View Protocol

Cell Line:

A549 cells.
Concentration:

0, 10, 30, 50 μM.
Incubation Time:

72 h.
Result:

A significant increase in glycogen accumulation was detected at 10 μM of CP-91149 as compared with untreated cells with a maximal glycogen accumulation at 30 μM. Intracellular glycogen content decreased at 50 μM CP-91149, perhaps explained by additional pharmacological effects of the drug. The dose-dependent accumulation of intracellular glycogen in A549 cells by CP-91149 indicates that CP-91149 inhibits brain GP in tissue culture.

Chemical Information

CAS. Nr. 186392-40-5
Appearance Solid
Molecular Weight 399.88
Formel C₂₁H₂₂ClN₃O₃
Color White to off-white
SMILES

O=C(C(N1)=CC2=C1C=CC(Cl)=C2)N[C@@H](CC3=CC=CC=C3)[C@@H](O)C(N(C)C)=O
Versand

Room temperature in continental US; may vary elsewhere.

Speicherung

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

Publications (9)

All Bio/Physico-chemical AssayCell Proliferation/Viability AssayWB

Sort by:

Journal Impact Factor

Nat Commun

Mitochondrial-cytochrome c oxidase II promotes glutaminolysis to sustain tumor cell survival upon glucose deprivation. [Abstract]

2025 Jan 2;16(1):212. PMID: 39747079
Cell Death Differ

Glycogen stores mediated by the p53-GYS1 feedback circuit engenders platinum resistance in ovarian clear cell carcinoma. [Abstract]

2025 Apr 11. PMID: 40210982
EMBO J

2026 Aug;45(16):5884-5918. PMID: 42458060
J Ginseng Res

Ginsenoside Rg5 promotes wound healing in diabetes by reducing the negative regulation of SLC7A11 on the efferocytosis of dendritic cells. [Abstract]

2023 Nov;47(6):784-794. PMID: 38107390

CP-91149 purchased from MedChemExpress. Usage Cited in: J Ginseng Res. 2023 Nov;47(6):784-794. [Abstract]

CP-91149 (a glycogen phosphorylase inhibitor) restored glycogen levels in ginsenoside Rg5-treated BMDCs and cDC1s.

CP-91149 purchased from MedChemExpress. Usage Cited in: J Ginseng Res. 2023 Nov;47(6):784-794. [Abstract]

CP-91149 significantly weakened ginsenoside Rg5-dependent elevation in efferocytosis.
FASEB J

Desaminotyrosine is a redox-active microbial metabolite that bolsters macrophage antimicrobial functions while attenuating IL-6 production. [Abstract]

2024 Jul 31;38(14):e23844. PMID: 39046365
J Hepatocell Carcinoma

IL-6 Released from Hepatic Stellate Cells Promotes Glycolysis and Migration of HCC Through the JAK1/vWF/TGFB1 Axis. [Abstract]

2024 Jul 5:11:1295-1310. PMID: 38983936
Comp Biochem Physiol Part D Genomics Proteomics

Deciphering multi-organ protein regulatory strategies in the Asian frog, Pelophylax nigromaculatus during hibernation to elucidate energy homeostasis maintenance mechanisms. [Abstract]

2025 Aug 8:56:101602. PMID: 40795786
Patent

US20240325326A1.
Heliyon

Integrated genomic and proteomic analyses identify PYGL as a novel experimental therapeutic target for clear cell renal cell carcinoma. [Abstract]

2024 Mar 16;10(6):e28295. PMID: 38545181

CP-91149 purchased from MedChemExpress. Usage Cited in: Heliyon. 2024 Mar 16;10(6):e28295. [Abstract]

Drug synergy matrix of sunitinib and CP-91149 (2.5-100 μM) in Caki-1-R and ACHN-R cells.

CP-91149 purchased from MedChemExpress. Usage Cited in: Heliyon. 2024 Mar 16;10(6):e28295. [Abstract]

Dose-response curves were compared between sunitinib and the combination of sunitinib with CP-91149 (0-100 μM) in Caki-1-R and ACHN-R cells.

CP-91149 purchased from MedChemExpress. Usage Cited in: Heliyon. 2024 Mar 16;10(6):e28295. [Abstract]

Combination of sunitinib and CP-91149 enhances DNA damage and apoptosis in ccRCC cells.

Lösungsmittel & Löslichkeit

In Vitro:

DMSO : 100 mg/mL (250.08 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

2.5008 mL

12.5038 mL

25.0076 mL

5 mM

0.5002 mL

2.5008 mL

5.0015 mL

10 mM

0.2501 mL

1.2504 mL

2.5008 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Molaritätsrechner

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Konzentration Konzentration

Volumen Volumen

Molecular Weight Molecular Weight

Verdünnungsrechner

Konzentration _{(Stammlösung)} × Volumen _{(Stammlösung)} = Konzentration _{(Ziellösung)} × Volumen _{(Ziellösung)}

Konzentration _{(Stammlösung)} Konzentration _{(Stammlösung)}

Volumen _{(Stammlösung)} Volumen _{(Stammlösung)}

Konzentration _{(Ziellösung)} Konzentration _{(Ziellösung)}

Volumen _{(Ziellösung)} Volumen _{(Ziellösung)}

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.5 mg/mL (6.25 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.5 mg/mL (6.25 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Protokoll

All Signal Pathway Related

Research Protocol for Endocrine Diseases
Endocrine diseases often arise from disrupted hormone production, hormone signaling, or target-tissue responsiveness; for diabetes-focused endocrine disease models, insulin signaling regulates glucose uptake, hepatic glucose output, lipid metabolism, and β-cell compensation. Type 2 diabetes develops through interacting defects in insulin resistance, β-cell dysfunction, adipose inflammation, hepatic glucose overproduction, altered incretin signaling, and ectopic lipid metabolism. A major unresolved question is whether endocrine dysfunction is driven primarily by target-tissue insulin resistance, intrinsic β-cell failure, immune/inflammatory stress, or combined multi-organ failure that differs by disease stage.
Research Protocol for Metabolic Diseases
AMP-activated protein kinase, AMPK, is a conserved cellular energy sensor that responds to reduced cellular energy status and coordinates metabolism by increasing ATP-generating catabolic pathways while suppressing ATP-consuming anabolic processes. In metabolic disease research, the AMPK pathway is experimentally relevant because it regulates hepatic lipid synthesis, fatty acid oxidation, glucose production, skeletal-muscle glucose disposal, mTORC1-linked biosynthesis, autophagy, mitochondrial homeostasis, and whole-body energy balance. The central pathway logic is that energy stress, metformin, exercise-like stimulation, or direct AMPK activators increase AMPKα Thr172 phosphorylation and downstream substrate phosphorylation, including ACC and RAPTOR. Phosphorylation of ACC suppresses lipogenesis and supports fatty acid oxidation, whereas phosphorylation of RAPTOR suppresses mTORC1 signaling and links cellular energy status to growth and protein synthesis control. The pathway is linked

Reinheit & Dokumentation

Select Batch:

Reinheit: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (275 KB)
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

Verweise

[1]. Carlos Lerín, et al. Regulation of glycogen metabolism in cultured human muscles by the glycogen phosphorylase inhibitor CP-91149. 2004 Mar 15; 378(Pt 3): 1073–1077.

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	2.5008 mL	12.5038 mL	25.0076 mL	62.5191 mL
	5 mM	0.5002 mL	2.5008 mL	5.0015 mL	12.5038 mL
	10 mM	0.2501 mL	1.2504 mL	2.5008 mL	6.2519 mL
	15 mM	0.1667 mL	0.8336 mL	1.6672 mL	4.1679 mL
	20 mM	0.1250 mL	0.6252 mL	1.2504 mL	3.1260 mL
	25 mM	0.1000 mL	0.5002 mL	1.0003 mL	2.5008 mL
	30 mM	0.0834 mL	0.4168 mL	0.8336 mL	2.0840 mL
	40 mM	0.0625 mL	0.3126 mL	0.6252 mL	1.5630 mL
	50 mM	0.0500 mL	0.2501 mL	0.5002 mL	1.2504 mL
	60 mM	0.0417 mL	0.2084 mL	0.4168 mL	1.0420 mL
	80 mM	0.0313 mL	0.1563 mL	0.3126 mL	0.7815 mL
	100 mM	0.0250 mL	0.1250 mL	0.2501 mL	0.6252 mL

Bioz

Keywords

CP-91149

9 Cited Publications

100 mg Angebot einholen

Subscribe to the

MedChemExpress

Newsletter

Produktname:
Art. -Nr.:
Menge:
MCE Japan Authorized Agent:

Produktname:
CAS. Nr.:
Species:
Reinheit:
Menge:

CP-91149

Publications Citing Use of MedChemExpress (MCE) CP-91149